





**Table 2**  
**Incidence of TEAE at least possibly related (>2.5% in any arm\*) according to concomitant CBZ, LTG, LEV**

Dictionary-Derived Term	CBZ					LTG					LEV																			
	ESL Total	ESL 1200 mg	ESL 800 mg	ESL 400 mg	Placebo	ESL Total	ESL 1200 mg	ESL 800 mg	ESL 400 mg	Placebo	ESL Total	ESL 1200 mg	ESL 800 mg	ESL 400 mg	Placebo															
	155	58	61	36	54	29	11	11	7	15	23	9	12	2	8															
Dizziness	26	16.8	12	20.7	11	18	3	8.3	3	5.6	4	13.8	1	9.1	3	27.3	0	0	1	6.7	1	4.3	1	11.1	0	0	0	0	0	0
Nausea	16	10.3	9	15.5	5	8.2	2	5.6	2	3.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Somnolence	15	9.7	8	13.8	4	6.6	3	8.3	5	9.3	3	10.3	1	9.1	1	9.1	1	14.3	0	0	1	4.3	0	0	1	8.3	0	0	1	12.5
Vomiting	9	5.8	7	12.1	2	3.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Diplopia	10	6.5	6	10.3	3	4.9	1	2.8	0	0	1	3.4	0	0	1	9.1	0	0	0	0	0	0	0	0	0	0	0	0	0	
Headache	8	5.2	3	5.2	3	4.9	2	5.6	3	5.6	1	3.4	0	0	1	9.1	0	0	0	0	2	8.7	1	11.1	1	8.3	0	0	0	0
Vertigo	5	3.2	3	5.2	1	1.6	1	2.8	0	0	2	6.9	0	0	1	9.1	1	14.3	0	0	0	0	0	0	0	0	0	0	0	0
Asthenia	4	2.6	3	5.2	0	0	1	2.8	0	0	1	3.4	0	0	1	9.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ataxia	4	2.6	2	3.4	1	1.6	1	2.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Vision blurred	3	1.9	2	3.4	0	0	1	2.8	0	0	1	3.4	0	0	0	0	1	14.3	0	0	0	0	0	0	0	0	0	0	0	0
Balance disorder	3	1.9	2	3.4	1	1.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood sodium decreased	3	1.9	2	3.4	0	0	1	2.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fatigue	3	1.9	1	1.7	1	1.6	1	2.8	1	1.9	1	3.4	0	0	1	9.1	0	0	1	6.7	1	4.3	1	11.1	0	0	0	0	0	0

**Incidence of discontinuation due to TEAE (>1% in any arm\*\*) according to concomitant CBZ, LTG, or LEV**

Dictionary-Derived Term	CBZ					LTG					LEV																	
	ESL Total	ESL 1200 mg	ESL 800 mg	ESL 400 mg	Placebo	ESL Total	ESL 1200 mg	ESL 800 mg	ESL 400 mg	Placebo	ESL Total	ESL 1200 mg	ESL 800 mg	ESL 400 mg	Placebo													
	155	58	61	36	54	29	11	11	7	15	23	9	12	2	8													
Dizziness	9	5.8	6	10.3	3	4.9	0	0	0	0	0	0	0	0	0													
Nausea	5	3.2	5	8.6	0	0	0	0	0	0	0	0	0	0	0													
Vomiting	6	3.9	5	8.6	1	1.6	0	0	0	0	0	0	0	0	0													
Somnolence	3	1.9	3	5.2	0	0	0	0	1	1.9	0	0	0	0	0													
Asthenia	3	1.9	3	5.2	0	0	0	0	0	0	0	0	0	0	0													
Nervousness	2	1.3	2	3.4	0	0	0	0	0	0	0	0	0	0	0													
Insomnia	2	1.3	2	3.4	0	0	0	0	0	0	0	0	0	0	0													
Irritability	2	1.3	2	3.4	0	0	0	0	0	0	0	0	0	0	0													
Diplopia	2	1.3	1	1.7	1	1.6	0	0	0	0	1	3.4	0	0	1	9.1	0	0	0	0	0	0	0	0	0	0	0	0

\* Absolute frequency of TEAE at least possibly related > 2 (correction due to small numbers of subpopulation); \*\* Absolute frequency of incidence of discontinuation due to TEAE >1.(correction due to small numbers of subpopulation)  
 CBZ, carbamazepine; ESL, Eslicarbazepine acetate; LTG, lamotrigine; LEV, Levetiracetam; TEAE, Treatment Emergent Adverse Events